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Abstract
In 2003, the Journal of Translational Medicine was launched to foster the publication of high quality research in
both “bench-to-bedside” as well as ex vivo human observation. In spite of the success of several large-scale
observational studies, e.g. Framingham Heart Study, the opportunity to expand upon the ex vivo human
observation has remained limited within the field of translational medicine. We believe that this presents a
significant opportunity that merits consideration in both the planning and analysis of large scale observational
studies and can contribute greatly to expanding our approaches in translational medicine
Editorial
The Journal of Translational Medicine (JTM) was
launched in 2003 with an editorial titled “Translational
Medicine: A two-way road”. In the following years,
through the dedicated efforts of its editorial and advi-
sory boards, dedicated reviewers and excellent
researcher submissions, it has established a solid reputa-
tion in the area of translational medicine although, by
necessity (based on submission), it has primarily repre-
sented one-way on the two-way road, namely that of
moving from Bench-to-Bedside. As outlined in that ori-
ginal editorial, this is actually not surprising, but it is
suggestive that there is opportunity to examine how to
“develop traffic heading in the other direction”,f r o m
Bedside to Bench. In this editorial we focus on the use
of large epidemiological studies and the specific oppor-
tunity for them to play a significant role in translational
medicine.
In July, 2003, the editorial stated that “Translational
Research would be most useful to the scientific commu-
nity at large if journals would foster specific interest for
the publication of ex vivo human observation”.W e
believe that an important approach towards this goal
might be through the detailed analysis and interpreta-
tion of large scale observational data sets, collected with
the same quality standards as applied in clinical studies
or clinical trials, and used to identify new questions and
lead to potential hypotheses that foster further experi-
ment and analysis.
Observational studies differ from standard clinical stu-
dies in that they may involve the collection of observa-
tions of individuals over an extended period of time
without focusing on the specific comparison of “treated”
versus “untreated” groups [1]. Such studies may involve
the study of behaviors, responses, etc. in populations
where randomized experimental design might violate
ethical standards, e.g. risk of smoking on pregnancies, or
may be impractical, e.g. the relationship between a spe-
cific treatment and potential side-effects that may be
rare [2]. They focus on establishing association, not
proving cause and effect, but can be invaluable for use
in the design of more conventional, controlled clinical
studies. We would suggest, however, that for observa-
tional studies to be considered within JTM’s definition
of clinical practice, there are several qualities that such a
study needs to address in its design and implementation
and we outline these below. There are well known
examples of such studies: the Framingham Heart Study
[3], The Nurses Health Study [4], the Women’s Health
Initiative (which includes both conventional clinical stu-
dies as well as an observational study) [5] and the Sur-
veillance Epidemiology and End Results Database
(SEER) [6]. While these examples are primarily of US
origin, international large scale observational studies
need to also be acknowledged as to their relevance in
Translational Medicine, notably the Busselton Health
Study (Australia) [7] and the China-Cornell-Oxford
Study [8].
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issues that exist within such large population-based stu-
dies can form the basis for many more directed studies
which can lead to results of immediate clinical utility.
While conventional analytical methods, including para-
metric and non-parametric statistical analysis, can iden-
tify significant trends and research questions, more
recent approaches, including social network analysis,
can be used to identify hypotheses and patterns within
these complex data sets that m a yc u r r e n t l ye l u d em o r e
conventional investigations. This follows the adage of
“let the data speak for itself” without always having a
pre-determined way to examine and interpret it, and
would be particularly useful in integrating and analyzing
multi-disciplinary data resources. In addition, this
approach can contribute to helping clinicians and clini-
cal researchers realize the true complexity that underlies
the observational data and support further communica-
tion of “bedside"-focused needs with the “bench-based”
research community.
It has been pointed out that observational studies are
sometimes confused as providing an adequate basis for
“evidence-based” medicine and it is clear that such stu-
dies, as listed above, have yielded risk algorithms and
potential contraindications that have been used in clini-
cal practice, possibly without adequate validation [9].
We do not promote such use but actually support the
concept the whether research begins in the laboratory
or in an observational study, the potential conclusions
that can impact clinical practice, i.e. translational
research, still need, in both cases, full clinical validation
through the randomized clinical trial process. We read-
ily accept this as the next stage in moving “bench to
bedside” but do not always utilize this approach in mov-
ing from “observational study/bedside to bench to bed-
side”. Thus the Framingham Cardiac Risk Algorithms
and the Gail Model for Breast Cancer Risk (and its deri-
vatives) all require the same rigor in validation that ana-
logous results from analyzing a biomarker in a pathway
in an animal model also deserve before moving into the
clinic.
We do believe that certain guidelines should be estab-
lished to support the development and operation of
observational studies towards their role in translational
medicine:
1. As most observational studies are longitudinal in
nature, a data collection instrument, i.e. questionnaire,
must be developed and maintained for consistency
through the study
2. Addition of new data elements and/or definitions
should be incorporated in follow on versions of the
study to support meta-analysis across the study while
allowing for new knowledge to be incorporated (see [3]
and [4])
3. Development of criteria to deal with the potential
biases in patient-generated vs physician/nurse generated
data needs to be validated
4. Development of processes for data validation to be
applied across the study period
5. Potentially provide access to data acquisition instru-
ment and definitions to support meta-data analysis
across studies while maintaining potential proprietary
concerns about the instrument
6. Development of statistically significant populations
to support application of parametric and non-parametric
data analysis (see [3-9])
7. Extend analysis of data beyond simple statistical
profiling to support the development of hypotheses lead-
ing to more conventional clinical studies
It may be an interesting example for the research
community in translational medicine to expand the
challenge to broaden the community to include epide-
miologists and systems modelers who focus on identify-
ing and extracting patterns from retrospective, ex vivo
observations. All this is intended to help our ultimate
goal of improving healthcare for the patient and the
physician.
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